{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T14:40:20Z","timestamp":1786804820951,"version":"build-2736575974"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2020,4,28]],"date-time":"2020-04-28T00:00:00Z","timestamp":1588032000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,4,28]],"date-time":"2020-04-28T00:00:00Z","timestamp":1588032000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Despite the availability of several antiemetics, clinical findings show that control of chemotherapy-induced nausea and vomiting (CINV) continues to be a serious concern for hematological patients, mainly for those receiving multiple-day (MD) and high-dose (HD) chemotherapy (CT). For CINV prophylaxis, 5-hydroxytryptamine type-3 receptor antagonists (5HT<jats:sub>3<\/jats:sub>-RAs) and neurokinin 1 receptor antagonists (NK<jats:sub>1<\/jats:sub>-RAs) are usually administered together with dexamethasone, which may increase the risk of serious infections in patients undergoing myeloablative treatment. The rationale of this multicenter, open-label and phase IIa study was to explore the efficacy of multiple doses of NEPA (netupitant\/palonosetron) given as an every-other-day regimen without dexamethasone in preventing CINV in patients with relapsed-refractory aggressive non-Hodgkin\u2019s lymphoma (R\/R-NHL), eligible for autologous stem cell transplantation (ASCT) and treated with MD-HD-CT. Seventy patients participated to the study. According to the adopted Fleming one-stage design, the primary endpoint of this study was achieved. The CR values were 87.1% (primary endpoint, overall phase: days 1\u20138), 88.6% (acute phase: days 1\u20136), and 98.6% (delayed phase: days 7\u20138), while complete control (CR with no more than mild nausea) was 85.7% (overall phase), 88.6% (acute phase), and 95.7% (delayed phase). Moderate and severe episodes of nausea were reported by less than 10% of patients in the overall phase and less than 5% in both the acute and delayed phases. Regarding safety, NEPA was well tolerated with only one adverse event (constipation) evaluated as possibly related to NEPA administration. In conclusion, our study demonstrated that multiple alternate dosing of NEPA without the addition of dexamethasone is highly effective for preventing nausea and vomiting in this difficult setting, with a good tolerability profile.<\/jats:p>","DOI":"10.1038\/s41409-020-0909-2","type":"journal-article","created":{"date-parts":[[2020,4,28]],"date-time":"2020-04-28T13:05:09Z","timestamp":1588079109000},"page":"2114-2120","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Efficacy and safety of multiple doses of NEPA without dexamethasone in preventing nausea and vomiting induced by multiple-day and high-dose chemotherapy in patients with non-Hodgkin\u2019s lymphoma undergoing autologous hematopoietic stem cell transplantation: a phase IIa, multicenter study"],"prefix":"10.1038","volume":"55","author":[{"given":"Nicola","family":"Di Renzo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Musso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosanna","family":"Scim\u00e8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Cupri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommasina","family":"Perrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"De Risi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Pastore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attilio","family":"Guarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Mengarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Benedetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizio","family":"Mazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Capria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Chiusolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Cupelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Federico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Bozzoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Rita","family":"Messa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Codega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erminio","family":"Bonizzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgina","family":"Specchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,28]]},"reference":[{"key":"909_CR1","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1177\/1078155209354655","volume":"16","author":"ME Trigg","year":"2010","unstructured":"Trigg ME, Higa GM. Chemotherapy-induced nausea and vomiting: antiemetic trials that impacted clinical practice. J Oncol Pharm Pr. 2010;16:233\u201344.","journal-title":"J Oncol Pharm Pr"},{"key":"909_CR2","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1517\/14656566.1.2.207","volume":"1","author":"SM Walton","year":"2000","unstructured":"Walton SM. Advances in use of the 5-HT3 receptor antagonists. Expert Opin Pharmacother. 2000;1:207\u201323.","journal-title":"Expert Opin Pharmacother"},{"key":"909_CR3","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1177\/107327489900600416","volume":"6","author":"R Miguel","year":"1999","unstructured":"Miguel R. Controlling chemotherapy-induced and postoperative nausea and vomiting. Cancer Control. 1999;6:393\u20137.","journal-title":"Cancer Control"},{"key":"909_CR4","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1007\/s005200050161","volume":"6","author":"GR Morrow","year":"1998","unstructured":"Morrow GR, Roscoe JA, Kirshner JJ, Hynes HE, Rosenbluth RJ. Anticipatory nausea and vomiting in the era of 5-HT3 antiemetics. Support Care Cancer. 1998;6:244\u20137.","journal-title":"Support Care Cancer"},{"key":"909_CR5","doi-asserted-by":"publisher","first-page":"3240","DOI":"10.1200\/JCO.2017.74.4789","volume":"35","author":"PJ Hesketh","year":"2017","unstructured":"Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, et al. Antiemetics: American Society of Clinical Oncology Clinical Practice guideline update. J Clin Oncol. 2017;35:3240\u201361.","journal-title":"J Clin Oncol"},{"key":"909_CR6","doi-asserted-by":"publisher","first-page":"v119","DOI":"10.1093\/annonc\/mdw270","volume":"27","author":"F Roila","year":"2016","unstructured":"Roila F, Molassiotis A, Herrstedt J, Aapro M, Gralla RJ, Bruera E, et al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol. 2016;27:v119\u201333.","journal-title":"Ann Oncol"},{"key":"909_CR7","doi-asserted-by":"publisher","first-page":"917","DOI":"10.2147\/TCRM.S89215","volume":"12","author":"V Lorusso","year":"2016","unstructured":"Lorusso V. Management of chemotherapy-induced nausea and vomiting by risk profile: role of netupitant\/palonosetron. Ther Clin Risk Manag. 2016;12:917\u201325.","journal-title":"Ther Clin Risk Manag"},{"key":"909_CR8","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) Antiemesis Version 1.2019. 2019. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/antiemesis.pdf."},{"key":"909_CR9","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/ddr.430280111","volume":"28","author":"RC Miller","year":"1993","unstructured":"Miller RC, Galvan M, Gittos MW, van Giersbergen PL, Moser PC, Fozard JR. Pharmacological properties of dolasetron, a potent and selective antagonist at 5HT3 receptors. Drug Dev Res. 1993;28:87\u201393.","journal-title":"Drug Dev Res"},{"key":"909_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00003495-199600525-00003","volume":"52","author":"AJ Hutt","year":"1996","unstructured":"Hutt AJ, Tan SC. Drug chirality and its clinical significance. Drug. 1996;52:1\u201312.","journal-title":"Drug"},{"key":"909_CR11","doi-asserted-by":"publisher","first-page":"173","DOI":"10.2165\/00003495-199855020-00002","volume":"55","author":"RE Gregory","year":"1998","unstructured":"Gregory RE, Ettinger DS. 5HT3 receptors antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy. Drugs. 1998;55:173\u201389.","journal-title":"Drugs"},{"key":"909_CR12","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1517\/14656566.2014.972366","volume":"15","author":"RM Navari","year":"2014","unstructured":"Navari RM. Palonosetron for the treatment of chemotherapy-induced nausea and vomiting. Expert Opin Pharmacother. 2014;15:2599\u2013608.","journal-title":"Expert Opin Pharmacother"},{"key":"909_CR13","doi-asserted-by":"publisher","first-page":"140","DOI":"10.3816\/SCT.2006.n.011","volume":"3","author":"GK Reddy","year":"2006","unstructured":"Reddy GK, Gralla RJ, Hesketh PJ. Novel neurokinin-1 antagonists as antiemetics for the treatment of chemotherapy-induced emesis. Support Cancer Ther. 2006;3:140\u20132.","journal-title":"Support Cancer Ther"},{"key":"909_CR14","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.peptides.2012.06.010","volume":"37","author":"A Rizzi","year":"2012","unstructured":"Rizzi A, Campi B, Camarda V, Molinari S, Cantoreggi S, Regoli D, et al. In vitro and in vivo pharmacological characterization of the novel NK1 receptor selective antagonist netupitant. Peptides. 2012;37:86\u201397.","journal-title":"Peptides"},{"key":"909_CR15","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1093\/annonc\/mdu101","volume":"25","author":"M Aapro","year":"2014","unstructured":"Aapro M, Rugo H, Rossi G, Rizzi G, Borroni ME, Bondarenko I, et al. A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. Ann Oncol. 2014;25:1328\u201333.","journal-title":"Ann Oncol"},{"key":"909_CR16","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1093\/annonc\/mdu110","volume":"25","author":"PJ Hesketh","year":"2014","unstructured":"Hesketh PJ, Rossi G, Rizzi G, Palmas M, Alyasova A, Bondarenko I, et al. Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study. Ann Oncol. 2014;25:1340\u20136.","journal-title":"Ann Oncol"},{"key":"909_CR17","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1093\/annonc\/mdu096","volume":"25","author":"RJ Gralla","year":"2014","unstructured":"Gralla RJ, Bosnjak SM, Hontsa A, Balser C, Rizzi G, Rossi G, et al. A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy. Ann Oncol. 2014;25:1333\u20139.","journal-title":"Ann Oncol"},{"key":"909_CR18","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.bbmt.2012.07.019","volume":"19","author":"PJ Stiff","year":"2013","unstructured":"Stiff PJ, Fox-Geiman MP, Kiley K, Rychlik K, Parthasarathy M, Fletcher-Gonzalez D, et al. Prevention of nausea and vomiting associated with stem cell transplant: results of a prospective, randomized trial of aprepitant used with highly emetogenic preparative regimens. Biol Blood Marrow Transpl. 2013;19:49\u201355.","journal-title":"Biol Blood Marrow Transpl"},{"key":"909_CR19","doi-asserted-by":"publisher","first-page":"3413","DOI":"10.1200\/JCO.2013.55.0095","volume":"32","author":"T Schmitt","year":"2014","unstructured":"Schmitt T, Goldschmidt H, Neben K, Freiberger A, H\u00fcsing J, Gronkowski M, et al. Aprepitant, granisetron, and dexamethasone for prevention of chemotherapy-induced nausea and vomiting after high-dose melphalan in autologous transplantation for multiple myeloma: results of a randomized, placebo-controlled phase III trial. J Clin Oncol. 2014;32:3413\u201320.","journal-title":"J Clin Oncol"},{"key":"909_CR20","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000371523","volume":"89","author":"A Svanberg","year":"2015","unstructured":"Svanberg A, Birgeg\u00e5rd G. Addition of aprepitant (Emend\u00ae) to standard antiemetic regimen continued for 7 days after chemotherapy for stem cell transplantation provides significant reduction of vomiting. Oncology. 2015;89:31\u20136.","journal-title":"Oncology"},{"key":"909_CR21","doi-asserted-by":"publisher","first-page":"3107","DOI":"10.1016\/j.transproceed.2011.08.010","volume":"43","author":"W Pielichowski","year":"2011","unstructured":"Pielichowski W, Barzal J, Gawronski K, Mlot B, Oborska S, Wasko-Grabowska A, et al. A triple-drug combination to prevent nausea and vomiting following BEAM chemotherapy before autologous hematopoietic stem cell transplantation. Transpl Proc. 2011;43:3107\u201310.","journal-title":"Transpl Proc"},{"key":"909_CR22","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ejphar.2013.10.008","volume":"722","author":"CC Chu","year":"2014","unstructured":"Chu CC, Hsing CH, Shieh JP, Chien CC, Ho CM, Wang JJ. The cellular mechanisms of the antiemetic action of dexamethasone and related glucocorticoids against vomiting. Eur J Pharm. 2014;722:48\u201354.","journal-title":"Eur J Pharm"},{"issue":"Suppl 1","key":"909_CR23","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1093\/annonc\/9.suppl_1.S15","volume":"9","author":"N Mounier","year":"1998","unstructured":"Mounier N, Gisselbrecht C. Conditioning regimens before transplantation in patients with aggressive non-Hodgkin\u2019s lymphoma. Ann Oncol. 1998;9 Suppl 1:S15\u201321.","journal-title":"Ann Oncol"},{"key":"909_CR24","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1053\/j.semnuclmed.2015.10.009","volume":"46","author":"A Shimoni","year":"2016","unstructured":"Shimoni A, Zwas ST. Radioimmunotherapy and autologous stem-cell transplantation in the treatment of B-cell non-Hodgkin lymphoma. Semin Nucl Med. 2016;46:119\u201325.","journal-title":"Semin Nucl Med"},{"key":"909_CR25","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/bmt.2008.257","volume":"42","author":"ME Trigg","year":"2008","unstructured":"Trigg ME, Inverso DM. Nausea and vomiting with high-dose chemotherapy and stem cell rescue therapy: a review of antiemetic regimens. Bone Marrow Transpl. 2008;42:501\u20136.","journal-title":"Bone Marrow Transpl"},{"key":"909_CR26","doi-asserted-by":"publisher","first-page":"51","DOI":"10.6004\/jnccn.2007.0007","volume":"5","author":"RM Navari","year":"2007","unstructured":"Navari RM. Prevention of emesis from multiple-day and high-dose chemotherapy regimens. J Natl Compr Cancer Netw. 2007;5:51\u20139.","journal-title":"J Natl Compr Cancer Netw"},{"key":"909_CR27","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s00520-008-0510-5","volume":"17","author":"M Musso","year":"2009","unstructured":"Musso M, Scalone R, Bonanno V. Palonosetron (Aloxi) and dexamethasone for the prevention of acute and delayed nausea and vomiting in patients receiving multiple-day chemotherapy. Support Care Cancer. 2009;17:205\u20139.","journal-title":"Support Care Cancer"},{"key":"909_CR28","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.2217\/fon.14.132","volume":"10","author":"A Mirabile","year":"2014","unstructured":"Mirabile A, Celio L, Magni M, Bonizzoni E, Gianni AM, Di Nicola M. Evaluation of an every-other-day palonosetron schedule to control emesis in multiple-day high-dose chemotherapy. Future Oncol. 2014;10:2569\u201378.","journal-title":"Future Oncol"},{"key":"909_CR29","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1093\/annonc\/mdl347","volume":"18","author":"SM Grunberg","year":"2007","unstructured":"Grunberg SM. Antiemetic activity of corticosteroids in patients receiving cancer chemotherapy: dosing, efficacy, and tolerability analysis. Ann Oncol. 2007;18:233\u201340.","journal-title":"Ann Oncol"},{"key":"909_CR30","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s10549-012-2205-3","volume":"136","author":"J Vardy","year":"2012","unstructured":"Vardy J, Pond G, Dodd A, Warr D, Seruga B, Clemons M, et al. A randomized double-blind placebo-controlled cross-over trial of the impact on quality of life of continuing dexamethasone beyond 24 h following adjuvant chemotherapy for breast cancer. Breast Cancer Res Treat. 2012;136:143\u201351.","journal-title":"Breast Cancer Res Treat"},{"key":"909_CR31","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1007\/s00520-010-0974-y","volume":"19","author":"N Di Renzo","year":"2011","unstructured":"Di Renzo N, Montanini A, Mannina D, Dondi A, Muci S, Mancuso S, et al. Single-dose palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with aggressive non-Hodgkin\u2019s lymphoma receiving moderately emetogenic chemotherapy containing steroids: results of a phase II study from the Gruppo Italiano per lo Studio dei Linfomi (GISL). Support Care Cancer. 2011;19:1505\u201310.","journal-title":"Support Care Cancer"},{"key":"909_CR32","doi-asserted-by":"publisher","first-page":"544","DOI":"10.3109\/10428194.2013.813498","volume":"55","author":"BS Choi","year":"2014","unstructured":"Choi BS, Borsaru GP, Ballinari G, Voisin D, Di Renzo N. Multicenter phase IV study of palonosetron in the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with non-Hodgkin lymphomas undergoing repeated cycles of moderately emetogenic chemotherapy. Leuk Lymphoma. 2014;55:544\u201350.","journal-title":"Leuk Lymphoma"},{"key":"909_CR33","volume-title":"Akynzeo\u00ae (netupitant and palonosetron) [prescribing information]","author":"Eisai Inc.","year":"2014","unstructured":"Eisai Inc. Akynzeo\u00ae (netupitant and palonosetron) [prescribing information]. Woodcliff Lake, NJ: Eisai Inc; 2014."}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41409-020-0909-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-020-0909-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-020-0909-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:18:12Z","timestamp":1684617492000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-020-0909-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,28]]},"references-count":33,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["909"],"URL":"https:\/\/doi.org\/10.1038\/s41409-020-0909-2","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,28]]},"assertion":[{"value":"25 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"PC is an employee of Italfarmaco SpA. Other authors have no competing interests to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}